Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel-CRMP-2 signaling complex

Sarah M. Wilson, Joel M. Brittain, Andrew D. Piekarz, Carrie J. Ballard, Matthew S. Ripsch, Theodore R. Cummins, Joyce H. Hurley, May Khanna, Nathan M. Hammes, Brian C. Samuels, Fletcher A. White, Rajesh Khanna

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The N-type voltage-gated calcium channel (Ca v2.2) has gained immense prominence in the treatment of chronic pain. While decreased channel function is ultimately anti-nociceptive, directly targeting the channel can lead to multiple adverse side effects. Targeting modulators of channel activity may facilitate improved analgesic properties associated with channel block and a broader therapeutic window. A novel interaction between Ca v2.2 and collapsin response mediator protein 2 (CRMP-2) positively regulates channel function by increasing surface trafficking. We recently identified a CRMP-2 peptide (TAT-CBD3), which effectively blocks this interaction, reduces or completely reverses pain behavior in a number of inflammatory and neuropathic models. Importantly, TAT-CBD3 did not produce many of the typical side effects often observed with Ca v2.2 inhibitors. Notably chronic pain mechanisms offer unique challenges as they often encompass a mix of both neuropathic and inflammatory elements, whereby inflammation likely causes damage to the neuron leading to neuropathic pain, and neuronal injury may produce inflammatory reactions. To this end, we sought to further disseminate the ability of TAT-CBD3 to alter behavioral outcomes in two additional rodent pain models. While we observed that TAT-CBD3 reversed mechanical hypersensitivity associated with a model of chronic inflammatory pain due to lysophosphatidylcholine-induced sciatic nerve focal demyelination (LPC), injury to the tibial nerve (TNI) failed to respond to drug treatment. Moreover, a single amino acid mutation within the CBD3 sequence demonstrated amplified Ca v2.2 binding and dramatically increased efficacy in an animal model of migraine. Taken together, TAT-CBD3 potentially represents a novel class of therapeutics targeting channel regulation as opposed to the channel itself.

Original languageEnglish (US)
JournalChannels
Volume5
Issue number5
DOIs
StatePublished - Jan 1 2011

Fingerprint

N-Type Calcium Channels
Chronic Pain
Peptides
Drug therapy
Pain
Tibial Nerve
Lysophosphatidylcholines
Aptitude
Wounds and Injuries
Neuralgia
Demyelinating Diseases
Sciatic Nerve
Calcium Channels
Therapeutics
Migraine Disorders
Modulators
Neurons
Analgesics
Rodentia
Hypersensitivity

Keywords

  • Chronic pain
  • CRMP-2
  • Migraine
  • N-type voltage-gated calcium channel/Ca 2.2
  • Pain therapeutics
  • Peptide

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry

Cite this

Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel-CRMP-2 signaling complex. / Wilson, Sarah M.; Brittain, Joel M.; Piekarz, Andrew D.; Ballard, Carrie J.; Ripsch, Matthew S.; Cummins, Theodore R.; Hurley, Joyce H.; Khanna, May; Hammes, Nathan M.; Samuels, Brian C.; White, Fletcher A.; Khanna, Rajesh.

In: Channels, Vol. 5, No. 5, 01.01.2011.

Research output: Contribution to journalArticle

Wilson, Sarah M. ; Brittain, Joel M. ; Piekarz, Andrew D. ; Ballard, Carrie J. ; Ripsch, Matthew S. ; Cummins, Theodore R. ; Hurley, Joyce H. ; Khanna, May ; Hammes, Nathan M. ; Samuels, Brian C. ; White, Fletcher A. ; Khanna, Rajesh. / Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel-CRMP-2 signaling complex. In: Channels. 2011 ; Vol. 5, No. 5.
@article{02845015332446dfbdfdf71f332410af,
title = "Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel-CRMP-2 signaling complex",
abstract = "The N-type voltage-gated calcium channel (Ca v2.2) has gained immense prominence in the treatment of chronic pain. While decreased channel function is ultimately anti-nociceptive, directly targeting the channel can lead to multiple adverse side effects. Targeting modulators of channel activity may facilitate improved analgesic properties associated with channel block and a broader therapeutic window. A novel interaction between Ca v2.2 and collapsin response mediator protein 2 (CRMP-2) positively regulates channel function by increasing surface trafficking. We recently identified a CRMP-2 peptide (TAT-CBD3), which effectively blocks this interaction, reduces or completely reverses pain behavior in a number of inflammatory and neuropathic models. Importantly, TAT-CBD3 did not produce many of the typical side effects often observed with Ca v2.2 inhibitors. Notably chronic pain mechanisms offer unique challenges as they often encompass a mix of both neuropathic and inflammatory elements, whereby inflammation likely causes damage to the neuron leading to neuropathic pain, and neuronal injury may produce inflammatory reactions. To this end, we sought to further disseminate the ability of TAT-CBD3 to alter behavioral outcomes in two additional rodent pain models. While we observed that TAT-CBD3 reversed mechanical hypersensitivity associated with a model of chronic inflammatory pain due to lysophosphatidylcholine-induced sciatic nerve focal demyelination (LPC), injury to the tibial nerve (TNI) failed to respond to drug treatment. Moreover, a single amino acid mutation within the CBD3 sequence demonstrated amplified Ca v2.2 binding and dramatically increased efficacy in an animal model of migraine. Taken together, TAT-CBD3 potentially represents a novel class of therapeutics targeting channel regulation as opposed to the channel itself.",
keywords = "Chronic pain, CRMP-2, Migraine, N-type voltage-gated calcium channel/Ca 2.2, Pain therapeutics, Peptide",
author = "Wilson, {Sarah M.} and Brittain, {Joel M.} and Piekarz, {Andrew D.} and Ballard, {Carrie J.} and Ripsch, {Matthew S.} and Cummins, {Theodore R.} and Hurley, {Joyce H.} and May Khanna and Hammes, {Nathan M.} and Samuels, {Brian C.} and White, {Fletcher A.} and Rajesh Khanna",
year = "2011",
month = "1",
day = "1",
doi = "10.4161/chan.5.5.17363",
language = "English (US)",
volume = "5",
journal = "Channels",
issn = "1933-6950",
publisher = "Landes Bioscience",
number = "5",

}

TY - JOUR

T1 - Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel-CRMP-2 signaling complex

AU - Wilson, Sarah M.

AU - Brittain, Joel M.

AU - Piekarz, Andrew D.

AU - Ballard, Carrie J.

AU - Ripsch, Matthew S.

AU - Cummins, Theodore R.

AU - Hurley, Joyce H.

AU - Khanna, May

AU - Hammes, Nathan M.

AU - Samuels, Brian C.

AU - White, Fletcher A.

AU - Khanna, Rajesh

PY - 2011/1/1

Y1 - 2011/1/1

N2 - The N-type voltage-gated calcium channel (Ca v2.2) has gained immense prominence in the treatment of chronic pain. While decreased channel function is ultimately anti-nociceptive, directly targeting the channel can lead to multiple adverse side effects. Targeting modulators of channel activity may facilitate improved analgesic properties associated with channel block and a broader therapeutic window. A novel interaction between Ca v2.2 and collapsin response mediator protein 2 (CRMP-2) positively regulates channel function by increasing surface trafficking. We recently identified a CRMP-2 peptide (TAT-CBD3), which effectively blocks this interaction, reduces or completely reverses pain behavior in a number of inflammatory and neuropathic models. Importantly, TAT-CBD3 did not produce many of the typical side effects often observed with Ca v2.2 inhibitors. Notably chronic pain mechanisms offer unique challenges as they often encompass a mix of both neuropathic and inflammatory elements, whereby inflammation likely causes damage to the neuron leading to neuropathic pain, and neuronal injury may produce inflammatory reactions. To this end, we sought to further disseminate the ability of TAT-CBD3 to alter behavioral outcomes in two additional rodent pain models. While we observed that TAT-CBD3 reversed mechanical hypersensitivity associated with a model of chronic inflammatory pain due to lysophosphatidylcholine-induced sciatic nerve focal demyelination (LPC), injury to the tibial nerve (TNI) failed to respond to drug treatment. Moreover, a single amino acid mutation within the CBD3 sequence demonstrated amplified Ca v2.2 binding and dramatically increased efficacy in an animal model of migraine. Taken together, TAT-CBD3 potentially represents a novel class of therapeutics targeting channel regulation as opposed to the channel itself.

AB - The N-type voltage-gated calcium channel (Ca v2.2) has gained immense prominence in the treatment of chronic pain. While decreased channel function is ultimately anti-nociceptive, directly targeting the channel can lead to multiple adverse side effects. Targeting modulators of channel activity may facilitate improved analgesic properties associated with channel block and a broader therapeutic window. A novel interaction between Ca v2.2 and collapsin response mediator protein 2 (CRMP-2) positively regulates channel function by increasing surface trafficking. We recently identified a CRMP-2 peptide (TAT-CBD3), which effectively blocks this interaction, reduces or completely reverses pain behavior in a number of inflammatory and neuropathic models. Importantly, TAT-CBD3 did not produce many of the typical side effects often observed with Ca v2.2 inhibitors. Notably chronic pain mechanisms offer unique challenges as they often encompass a mix of both neuropathic and inflammatory elements, whereby inflammation likely causes damage to the neuron leading to neuropathic pain, and neuronal injury may produce inflammatory reactions. To this end, we sought to further disseminate the ability of TAT-CBD3 to alter behavioral outcomes in two additional rodent pain models. While we observed that TAT-CBD3 reversed mechanical hypersensitivity associated with a model of chronic inflammatory pain due to lysophosphatidylcholine-induced sciatic nerve focal demyelination (LPC), injury to the tibial nerve (TNI) failed to respond to drug treatment. Moreover, a single amino acid mutation within the CBD3 sequence demonstrated amplified Ca v2.2 binding and dramatically increased efficacy in an animal model of migraine. Taken together, TAT-CBD3 potentially represents a novel class of therapeutics targeting channel regulation as opposed to the channel itself.

KW - Chronic pain

KW - CRMP-2

KW - Migraine

KW - N-type voltage-gated calcium channel/Ca 2.2

KW - Pain therapeutics

KW - Peptide

UR - http://www.scopus.com/inward/record.url?scp=80052635029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052635029&partnerID=8YFLogxK

U2 - 10.4161/chan.5.5.17363

DO - 10.4161/chan.5.5.17363

M3 - Article

C2 - 21829088

AN - SCOPUS:80052635029

VL - 5

JO - Channels

JF - Channels

SN - 1933-6950

IS - 5

ER -